Copay help by condition · Neurological and neuromuscular · read 2026-11-10
Multiple Sclerosis (MS): which charitable copay funds are open
All 5 funds we hold for Multiple Sclerosis are closed or at capacity right now (read 2026-11-10).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Multiple Sclerosis
- WaitlistMultiple Sclerosis
Accessia Health ·
Award level: not statedInsurance supported: not stated
The program page lists the program as At Capacity, Waitlist Open. Its tracks: privately insured track waitlist open (at capacity); publicly insured track waitlist open (at capacity). It shows no date. Source page
- Closed or at capacityMultiple Sclerosis
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed). Source page
- Closed or at capacityMultiple Sclerosis - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Closed. Source page
- Closed or at capacityMultiple sclerosis (MS)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $8,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
- Closed or at capacityMultiple sclerosis (MS) health equity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $8,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Multiple Sclerosis
10 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 7 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Mavenclad Cladribine Every route for this drug | Cladribine tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease in adults. Label on openFDA, read 2026-11-10 | MS Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Tecfidera Dimethyl Fumarate Every route for this drug | Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | MS Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Vumerity Diroximel Fumarate Every route for this drug | VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | MS Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Betaseron Interferon Beta-1b Every route for this drug | BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Ocrevus Ocrelizumab Every route for this drug | Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults ... Label on openFDA, read 2026-11-10 | Ocrevus Access Solutions (via Genentech) Genentech Patient Foundation MS Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Kesimpta Ofatumumab Every route for this drug | KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | MS Medication Assistance (Multiple Programs) Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
| Aubagio Teriflunomide Every route for this drug | Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | MS Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Copaxone Glatiramer Acetate | Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Avonex Interferon Beta-1a | REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
1 drug whose label names more than 8 conditions
Broad labels, such as corticosteroids, list many conditions in one sentence. They are shown apart so they do not crowd the drugs written for Multiple Sclerosis.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Acthar Corticotropin | Acute exacerbations of multiple sclerosis. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
No broader or more specific condition page for this one.
Group: Neurological and neuromuscular. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-10. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: multiple-sclerosis.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Multiple Sclerosis?
As read on 2026-11-10, none of the 5 funds we hold for Multiple Sclerosis say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Multiple Sclerosis?
Accessia Health, Good Days, HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-10). We do not promise a fund is still in that state today.